RDIF Partners With Dr. Reddy’s Labaoroties For Phase III Trials In India

Indian pharmaceutical company Dr. Reddy’s Laboratories Ltd. has teamed up with the Russian Direct Investment Fund (RDIF), to conduct clinical trials and distribute vaccine doses of the Russian Sputnik V vaccine in India.

The Hyderabad-based giant said that the vaccine has shown promising results in Phase 1 and Phase 2 clinical trials. Now, Phase 3 clinical trials will be conducted in India to meet the requirements of regulators. G.V. Prasad, co-chairman and managing director, Dr. Reddy’s Laboratories, said that the “Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India.” Once the concerned regulatory approvals are done, the company will be supplying around 100 Million doses of the vaccine in the country.

“The Sputnik V vaccine, which is based on a well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India,” RDIF said in a statement. This partnership doesn’t mean that Dr. Reddy’s will be manufacturing the vaccine, the Russian body is still looking for the manufacturers.

Dr. Reddy’s is not the first company who has bagged the partnership with the foreign entity. The Pune-based Serum Institute of India has come into an agreement with the British pharmaceutical and biopharmaceutical company AstraZeneca. According to the agreement, both the Indian-based company will manufacture 100 Million doses out of which, half of them will be distributed in India. AstraZeneca has partnered with Oxford University to conduct research and trials for the COVID-19 shield vaccine.

The Russian vaccine is currently being developed by the Gamaleya Research Institute. Last month, the vaccine’s Phase 1 and Phase 2 clinical trials were safely completed. Moreover, Russian President Vladimir Putin had announced that the Sputnik V vaccine was registered. According to the reports from Russian Health Ministry, the vaccine can provide immunity from coronavirus for up to two years.

Recently, Sputnik News reported that “Clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India, and Brazil will begin [in September].”  In the news report, RDIF head Kirill Dmitriev told that “We do recognize India’s potential to become a support for the production of the vaccine not only in Indian markets but for other countries too, and we have achieved certain agreements with the leading companies.”

Currently, India is the second-worst affected country from the coronavirus. As of writing, the country has recorded more than 97,000 patients and has crossed 1 Million inactive cases. The RDIF head said in an interview with CBNC that if all goes well, it can start delivering COVID-19 vaccines from November this year. According to the reports, 30 crores of doses will be produced in India.

Meanwhile, the Director of the US Centers for Disease Control and Prevention (CDC) Robert Redfield said that the COVID-19 vaccine will not be available to a huge percentage of the U.S. population before the second or third quarters of 2021. However, Trump countered the report saying that “I think he got the message maybe confused, maybe it was stated incorrectly.” “It could be announced in October, it could be announced a little bit after October,” he added.